Eric M. Dube Sells 50,691 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric M. Dube sold 50,691 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $20.21, for a total value of $1,024,465.11. Following the completion of the sale, the chief executive officer now owns 430,548 shares of the company’s stock, valued at approximately $8,701,375.08. This trade represents a 10.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $21.21 on Thursday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -4.66 and a beta of 0.72. The firm’s 50 day simple moving average is $18.74 and its 200-day simple moving average is $15.51. Travere Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $21.86.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on TVTX shares. Barclays upped their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Scotiabank upped their target price on Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Wedbush boosted their price target on Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. HC Wainwright raised their price objective on Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Finally, Cantor Fitzgerald assumed coverage on Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Institutional Trading of Travere Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Travere Therapeutics during the 4th quarter worth about $53,000. CWM LLC boosted its position in Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares in the last quarter. Quarry LP purchased a new position in Travere Therapeutics during the third quarter worth approximately $105,000. Baader Bank Aktiengesellschaft acquired a new stake in Travere Therapeutics in the fourth quarter valued at approximately $192,000. Finally, Diversified Trust Co purchased a new stake in shares of Travere Therapeutics in the third quarter valued at approximately $161,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.